
News
Novo Nordisk's US stock rose over 7% in after-hours trading, while Tonix Pharmaceuticals surged nearly 17%. The company's drugs Wegovy and Tonmya have received approval from the US FDA

Novo Nordisk's US stock rose over 7% in after-hours trading, while Tonix Pharmaceuticals surged nearly 17%. The company's drugs Wegovy and Tonmya have received approval from the US FDA